Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,500 shares, a drop of 70.0% from the March 31st total of 5,000 shares. Based on an average trading volume of 13,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Cocrystal Pharma in a research report on Thursday, April 4th.
Get Our Latest Stock Analysis on COCP
Cocrystal Pharma Trading Up 3.0 %
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.13. Research analysts anticipate that Cocrystal Pharma will post -2.31 EPS for the current year.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
See Also
- Five stocks we like better than Cocrystal Pharma
- Quiet Period Expirations Explained
- 3 Stocks Leading the U.S. Agriculture Comeback
- Stock Analyst Ratings and Canadian Analyst Ratings
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Are Dividend Champions? How to Invest in the Champions
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.